Compare Lucid Group Inc (LCID) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lucid Group Inc trades at $3.79 (market cap $1.51B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 6.7× Lucid Group Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LCID | XBI | |
|---|---|---|
Market Cap | $1.51B | $10.11B |
Volume | 12,333,745 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $21.92 | $169.55 |
52-Week Low | $3.79 | $104.99 |
Typical Hold Time | 45 Days | 38 Days |
Enterprise Value | $4.40B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.82, down 1.8% with a bearish technical outlook. The company faces significant financial challenges with negative profit margins (-249.21% net income margin) and consecutive earnings misses. Recent developments include strategic partnerships for autonomous vehicles and software updates, but cash burn remains elevated at -$2.93B operating cash flow in 2025.
LCID presents high-risk turnaround potential with analyst consensus target of $7.60 (99% upside) but requires successful execution on cost savings and new vehicle launches. Key risks include persistent cash burn, production delays, and competitive EV market pressures. The stock's viability hinges on management's ability to achieve targeted $1.4B cost savings and deliver the delayed Cosmos SUV.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
